Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.

Jose F. Leis, Steven Primack, Susan E. Schubach, Peter T. Curtin, Brian Druker, Richard Maziarz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.

Original languageEnglish (US)
JournalHaematologica.
Volume89
Issue number9
StatePublished - Sep 2004

Fingerprint

Leukostasis
Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lung
Tumor Lysis Syndrome
Leukocyte Count
Acute Myeloid Leukemia
Respiratory Insufficiency
Dyspnea
Protein-Tyrosine Kinases
Electrolytes
Fever
Imatinib Mesylate
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. / Leis, Jose F.; Primack, Steven; Schubach, Susan E.; Curtin, Peter T.; Druker, Brian; Maziarz, Richard.

In: Haematologica., Vol. 89, No. 9, 09.2004.

Research output: Contribution to journalArticle

@article{8daa69a3e834442db307709e477f7a5e,
title = "Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.",
abstract = "Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.",
author = "Leis, {Jose F.} and Steven Primack and Schubach, {Susan E.} and Curtin, {Peter T.} and Brian Druker and Richard Maziarz",
year = "2004",
month = "9",
language = "English (US)",
volume = "89",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "9",

}

TY - JOUR

T1 - Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.

AU - Leis, Jose F.

AU - Primack, Steven

AU - Schubach, Susan E.

AU - Curtin, Peter T.

AU - Druker, Brian

AU - Maziarz, Richard

PY - 2004/9

Y1 - 2004/9

N2 - Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.

AB - Pulmonary leukostasis is a rare but serious and often fatal complication of chronic myeloid leukemia (CML) in blast crisis and acute myeloid leukemia. Treatment options are limited for these patients. Imatinib mesylate (STI-571, Gleevec, Novartis) is a potent and selective inhibitor of the BCR-abl tyrosine kinase, the molecular abnormality that causes CML. The case of a 74-year-old man with a history of CML who presented in myeloid blast crisis with pulmonary leukostasis characterized by increasing dyspnea, hypoxemia, fever, and impending respiratory failure is reported. The patient was treated with single agent imatinib mesylate (IM) with rapid decrease in his white blood cell count (WBC) and marked improvement in his respiratory status. No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.

UR - http://www.scopus.com/inward/record.url?scp=33645861970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645861970&partnerID=8YFLogxK

M3 - Article

VL - 89

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -